Company news

Alterity Therapeutics Ltd. news in 2025

Alterity Therapeutics Ltd.'s news releases, calls and decks from 2025, newest first.

View company

Alterity Board Changes

November 20, 2025

Alterity Therapeutics to Present at the Bell Potter Healthcare Virtual Conference

November 12, 2025

Alterity Therapeutics Presents Promising Impact of ATH434 on Orthostatic Hypotension and Disease Progression in MSA at the 36th International Symposium on the Autonomic Nervous System

November 10, 2025

Alterity Therapeutics Presents Promising Impact of ATH434 on Orthostatic Hypotension and Disease Progression in MSAat the 36th International Symposium on the Autonomic Nervous System

November 9, 2025

Appendix 4C – Q1 FY26 Quarterly Cash Flow Report

November 2, 2025

Alterity Therapeutics: Appendix 4C – Q1 FY26 Quarterly Cash Flow Report

October 31, 2025

Alterity Therapeutics Presents Positive Data from ATH434 Phase 2 Trial at the 2025 International Congress of Parkinson’s Disease and Movement Disorders

October 9, 2025

Alterity Therapeutics Presents Positive Data from ATH434 Phase 2 Trial at the 2025 International Congress of Parkinson’s Disease and Movement Disorders

October 8, 2025

Alterity Therapeutics to Deliver Multiple Presentations at the 2025 International Congress of Parkinson’s Disease and Movement Disorders

October 2, 2025

Alterity Therapeutics Presents ATH434-201 Phase 2 Data at the American Neurological Association Annual Meeting

September 15, 2025

Alterity Therapeutics Presents ATH434-201 Phase 2 Data at the American Neurological Association Annual Meeting

September 14, 2025

Alterity Therapeutics Raises A$20.0 million in Strategic Placement

September 8, 2025

Alterity Raises A$20.0 million in Strategic Placement

September 8, 2025

Alterity Therapeutics Raises A$20.0 million in Strategic Placement

September 7, 2025

Trading Halt

September 3, 2025

Alterity Therapeutics to Present at the Biotech Showcase

September 2, 2025

Appendix 4E and 2025 Annual Report

August 29, 2025

Response to ASX Query Letters

August 4, 2025

Appendix 4C – Q4 FY25 Quarterly Cash Flow Report

July 30, 2025

Appendix 4C – Q4 FY25 Quarterly Cash Flow Report

July 29, 2025

Alterity Therapeutics Reports Positive Topline Data from Open-Label Phase 2 Clinical Trial of ATH434 in Multiple System Atrophy

July 28, 2025

Positive ATH434 Results from Open-Label Phase 2 Trial in MSA

July 28, 2025

Alterity Therapeutics Reports Positive Topline Data from Open-Label Phase 2 Clinical Trial of ATH434 in Multiple System Atrophy

July 27, 2025

Alterity Therapeutics Announces Publication on Novel MRI Endpoint from the bioMUSE Natural History Study

July 24, 2025

Peer-Reviewed Publication on Novel MRI Endpoint from bioMUSE

July 24, 2025

Response to ASX Price Query

July 13, 2025

Alterity Therapeutics to Provide Corporate Update in Fireside Chat

June 23, 2025

Alterity Therapeutics Prominently Featured at the International MSA Congress

May 12, 2025

Alterity Therapeutics Announces Multiple Oral and Poster Presentations to be Featured at the International MSA Congress

May 7, 2025

Alterity Therapeutics Granted U.S. FDA Fast Track Designation for ATH434 to Treat Multiple System Atrophy

May 5, 2025

Alterity Granted U.S. FDA Fast Track Designation for ATH434

May 4, 2025

Appendix 4C – Q3 FY25 Quarterly Cash Flow Report

April 30, 2025

Appendix 4C – Q3 FY25 Quarterly Cash Flow Report

April 29, 2025

Alterity Therapeutics Presents ATH434-201 Phase 2 Clinical Trial Results at European MSA Symposium

April 28, 2025

Options Prospectus

April 17, 2025

Alterity Therapeutics Presents Encouraging New Data from its ATH434 Phase 2 Trial in Multiple System Atrophy at the American Academy of Neurology Annual Meeting

April 10, 2025

Alterity Phase 2 Presentation at AAN 2025

April 10, 2025

Alterity Presents Encouraging New Phase 2 Data in MSA

April 10, 2025

Alterity Therapeutics Presents Encouraging New Data from its ATH434 Phase 2 Trial in Multiple System Atrophy at the American Academy of Neurology Annual Meeting

April 9, 2025

Alterity Therapeutics to Deliver an Oral Presentation of the Positive ATH434 Phase 2 Trial Results at the American Academy of Neurology Annual Meeting

April 3, 2025

Alterity Therapeutics Completes Last Patient Visit in ATH434-202 Open-Label Phase 2 Trial in Multiple System Atrophy

March 27, 2025

Alterity Completes Last Patient Visit in Open-Label Trial

March 27, 2025

Alterity raises A$40m to Advance ATH434 Development in MSA

February 9, 2025

Alterity Raises Funds for ATH434 BD and Clinical Activities

February 2, 2025

Positive ATH434 Phase 2 Results Led By Clinical Efficacy

January 29, 2025

Decks in 2025